HomeCompareBCAN vs PFE

BCAN vs PFE: Dividend Comparison 2026

BCAN yields 47.62% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $22.0K in total portfolio value· pulled ahead in Year 9
10 years
BCAN
BCAN
● Live price
47.62%
Share price
$4.20
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$6.86
Full BCAN calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — BCAN vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBCANPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BCAN + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BCAN pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BCAN
Annual income on $10K today (after 15% tax)
$4,047.62/yr
After 10yr DRIP, annual income (after tax)
$5.83/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $23,123.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BCAN + PFE for your $10,000?

BCAN: 50%PFE: 50%
100% PFE50/50100% BCAN
Portfolio after 10yr
$40.1K
Annual income
$13,608.70/yr
Blended yield
33.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BCAN
No analyst data
Altman Z
-3.2
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BCAN buys
0
PFE buys
0
No recent congressional trades found for BCAN or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBCANPFE
Forward yield47.62%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$29.0K$51.1K
Annual income after 10y$6.86$27,210.54
Total dividends collected$5.5K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BCAN vs PFE ($10,000, DRIP)

YearBCAN PortfolioBCAN Income/yrPFE PortfolioPFE Income/yrGap
1$13,081$2,380.95$9,161$701.38+$3.9KBCAN
2$15,452$1,455.38$8,610$859.79+$6.8KBCAN
3$17,337$803.36$8,366$1,081.25+$9.0KBCAN
4$18,972$421.19$8,483$1,405.66+$10.5KBCAN
5$20,515$215.38$9,084$1,907.24+$11.4KBCAN
6$22,060$108.83$10,418$2,732.78+$11.6KBCAN
7$23,659$54.69$13,007$4,193.56+$10.7KBCAN
8$25,343$27.41$18,010$7,005.87+$7.3KBCAN
9← crossover$27,130$13.72$28,216$12,979.89$1.1KPFE
10$29,036$6.86$51,081$27,210.54$22.0KPFE

BCAN vs PFE: Complete Analysis 2026

BCANStock

BYND Cannasoft Enterprises Inc. develops, markets, and sells customer relationship management (CRM) software products. It owns and markets Benefit CRM, a customer relationship management software product that enables small and medium-sized enterprises to optimize day-to-day functions, such as sales management, workforce management, contact center operations, and asset management; and New Cannabis CRM platform for the medical cannabis industry, as well as manages the construction, licensing, and operation of a cannabis farm and indoor cannabis growing facility. The company is based in Vancouver, Canada.

Full BCAN Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BCAN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BCAN vs SCHDBCAN vs JEPIBCAN vs OBCAN vs KOBCAN vs MAINBCAN vs JNJBCAN vs MRKBCAN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.